Chemical Structure (Tyvasodpi 01)
Not available.*
Tyvaso Dpi Kit
Product Images NDC 66302-620
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 65 technical images submitted to the FDA as part of the official labeling for Tyvaso Dpi (NDC 66302-620). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by United Therapeutics Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Tyvasodpi 02)
The text describes a comparison of the percentage of patients with a greater MWD (maximum walking distance) change between a drug called Tyvaso (with a sample size of 115) and a placebo (with a sample size of 120). The comparison is shown through a graph with a y-axis scale of <140, 120, 80, and 40, and an x-axis with increments of 20 from 0 to 100. The chart shows that the MWD change from baseline (in meters) is higher for the Tyvaso group compared to the placebo group.*
Figure 2 (Tyvasodpi 03)
This text presents the results of a clinical trial that compared the effect of a medication called Tyvaso versus a placebo in individuals with pulmonary arterial hypertension. The trial included a total of 120 subjects, with different ages and gender, but mainly from North America. The results show several variables, such as Baseline 6MWD (distance walked in six minutes), different age quartiles, etiology, and background therapy. Additionally, the table presents the Placebo-Corrected Median Treatment Effect of Tyvaso.*
Figure 3 (Tyvasodpi 04)
This appears to be a table showing study visit timelines and results of a medication's effects in weeks 4, 12, 15, and 16 on subjects. It also includes confidence interval percentages and median treatment effects in a placebo-controlled setting.*
Figure 4 (Tyvasodpi 05)
This is not a readable text.*
Figure 5 (Tyvasodpi 06)
Figure A (Tyvasodpi 07)
Figure B (Tyvasodpi 08)
Figure C (Tyvasodpi 09)
Figure D (Tyvasodpi 10)
This appears to be a list of doses, measured in mcg (micrograms), possibly for a medication or supplement. However, without additional context or information, it is not clear what these doses refer to or how they should be used.*
Figure E (Tyvasodpi 11)
Figure F (Tyvasodpi 12)
Figure H (Tyvasodpi 13)
Image (Tyvasodpi 14)
Image (Tyvasodpi 15)
Figure G (Tyvasodpi 16)
Image (Tyvasodpi 17)
Image (Tyvasodpi 18)
Image (Tyvasodpi 19)
The text is not available as it only includes color and a single word that is difficult to determine the context.*
Image (Tyvasodpi 20)
Figure J (Tyvasodpi 21)
Figure K (Tyvasodpi 22)
Figure I (Tyvasodpi 23)
The text provides information about two printer cartridges, one dark blue and one light blue. Additionally, it indicates that the memory or capacity of the cartridges is 32 megabytes and 48 megabytes respectively. There is insufficient information to determine what type of cartridges they are, what brand they belong to, or what printer they are compatible with.*
Figure L (Tyvasodpi 24)
Image (Tyvasodpi 25)
Image (Tyvasodpi 26)
Image (Tyvasodpi 27)
Image (Tyvasodpi 28)
Figure M (Tyvasodpi 29)
Figure N (Tyvasodpi 30)
Figure O (Tyvasodpi 31)
Figure P (Tyvasodpi 32)
Figure Q (Tyvasodpi 33)
Figure R (Tyvasodpi 34)
Image (Tyvasodpi 35)
Image (Tyvasodpi 36)
Image (Tyvasodpi 37)
Figure T (Tyvasodpi 38)
Figure U (Tyvasodpi 39)
Figure V (Tyvasodpi 40)
Figure W (Tyvasodpi 41)
Figure X (Tyvasodpi 42)
Figure Y (Tyvasodpi 43)
Figure Z (Tyvasodpi 44)
Figure Aa (Tyvasodpi 45)
Figure Ab (Tyvasodpi 46)
Figure Ac (Tyvasodpi 47)
Figure Ad (Tyvasodpi 48)
Figure Ae (Tyvasodpi 49)
Figure Af (Tyvasodpi 50)
Figure Ag (Tyvasodpi 51)
Figure Ai (Tyvasodpi 52)
Figure Ah (Tyvasodpi 53)
Principal Display Panel (16 mcg Maintenance Kit)
Principal Display Panel (16 mcg Institutional Kit)
TYVASO DPI is a medication containing treprostinil used for oral inhalation. It is available in an institutional kit, which includes multiple cartridges. It is not suitable for everyone and should only be used as prescribed by a medical professional. Some characters are not readable in the given text.*
Principal Display Panel (32 mcg Maintenance Kit)
Principal Display Panel (32 mcg Institutional Kit)
This is a description for the Institutional Kit of TYVASO DPI, which is used for oral inhalation only. The kit contains 16 cartridges, each with 32 meg per cartridge. It is not clear what the active ingredient is due to errors.*
Principal Display Panel (48 mcg Maintenance Kit)
Principal Display Panel (48 mcg Institutional Kit)
The text is a description of an "Institutional Kit" for oral inhalation. The kit includes 16 cartridges, each containing 48 meg per cartridge. The kit is not recommended for ventilation. The text also mentions "TYVASO DPI Sprepay | ks" (reprostni). The text provides some details related to usage and replacement of the inhalers.*
Principal Display Panel (64 mcg Maintenance Kit)
Principal Display Panel (64 mcg Institutional Kit)
This appears to be a description of an Institutional Kit intended for oral inhalation only. The kit contains 16 cartridges, each containing 84 meg per cartridge inhalers of TYVASO DPI (treprostinil) recommended dosage of 820 Pressing information. The instructions on how to use the kit are also included.*
Principal Display Panel (16 mcg 32 mcg Titration Kit)
Principal Display Panel (32 mcg 48 mcg Maintenance Kit)
Principal Display Panel (32 mcg 48 mcg Institutional Kit)
Principal Display Panel (16 mcg 32 mcg 48 mcg Titration Kit)
The text seems to be a product label for a Titration Kit called "TYVASO DPI". It may contain a drug ingredient called "treprostini" and some identification codes. However, some characters are not readable, so complete information cannot be obtained.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
